Barriers and Facilitators of Implementation of the Non-Hospital-Based Administration of Long-Acting Cabotegravir Plus Rilpivirine in People with HIV: Qualitative Data from the HOLA Study
Long-acting (LA) antiretroviral therapies for human immunodeficiency virus (HIV), such as injectable formulations of cabotegravir and rilpivirine (CAB+RPV LA), are now available. Considering the limited data on the out-of-hospital administration of this combination, evaluating the implementation str...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-07-01
|
| Series: | Viruses |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1999-4915/17/7/993 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849251902506663936 |
|---|---|
| author | Diana Hernández-Sánchez Juan M. Leyva-Moral Julian Olalla Eugènia Negredo on behalf of the HOLA Study Group |
| author_facet | Diana Hernández-Sánchez Juan M. Leyva-Moral Julian Olalla Eugènia Negredo on behalf of the HOLA Study Group |
| author_sort | Diana Hernández-Sánchez |
| collection | DOAJ |
| description | Long-acting (LA) antiretroviral therapies for human immunodeficiency virus (HIV), such as injectable formulations of cabotegravir and rilpivirine (CAB+RPV LA), are now available. Considering the limited data on the out-of-hospital administration of this combination, evaluating the implementation strategies needed is essential to support future clinical efforts. To gather data on barriers and facilitators of implementation for CAB+RPV LA in alternative outpatient facilities, this study used qualitative interviews informed by the Consolidated Framework for Implementation Research (CFIR), with 13 staff participating in the HOLA study (NCT06185452). Data analysis followed qualitative descriptive methods, assisted by Atlas.ti software version 22. The study adhered to the COREQ guidelines. Findings reveal five main factors to consider for implementation: operational and infrastructure adaptations, integrated management of human and organizational resources, need for coordination and follow-up, professional attitudes and work environment, and patient experience and patients’ needs perceived by professionals. This study emphasizes the comprehensive operational and infrastructure adaptations, adequate staff training, and supportive professional environment required for the successful implementation of CAB+RPV LA, while considering patients’ needs throughout the externalization process (trial registration number: NCT06643897). |
| format | Article |
| id | doaj-art-5b2b4feeb9be40ed81d0ed4f11bf4034 |
| institution | Kabale University |
| issn | 1999-4915 |
| language | English |
| publishDate | 2025-07-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Viruses |
| spelling | doaj-art-5b2b4feeb9be40ed81d0ed4f11bf40342025-08-20T03:56:46ZengMDPI AGViruses1999-49152025-07-0117799310.3390/v17070993Barriers and Facilitators of Implementation of the Non-Hospital-Based Administration of Long-Acting Cabotegravir Plus Rilpivirine in People with HIV: Qualitative Data from the HOLA StudyDiana Hernández-Sánchez0Juan M. Leyva-Moral1Julian Olalla2Eugènia Negredo3on behalf of the HOLA Study GroupLluita Contra les Infeccions, Hospital Universitari Germans Trias i Pujol, Ctra del Canyet S/N, 08916 Badalona, SpainGrup de Recerca Infemera en Vulnerabilitat i Salut, Departament d’Infermeria. Universitat Autonoma de Barcelona, 08015 Barcelona, SpainHospital Universitario Costa del Sol, 29603 Marbella, Málaga, SpainLluita Contra les Infeccions, Hospital Universitari Germans Trias i Pujol, Ctra del Canyet S/N, 08916 Badalona, SpainLong-acting (LA) antiretroviral therapies for human immunodeficiency virus (HIV), such as injectable formulations of cabotegravir and rilpivirine (CAB+RPV LA), are now available. Considering the limited data on the out-of-hospital administration of this combination, evaluating the implementation strategies needed is essential to support future clinical efforts. To gather data on barriers and facilitators of implementation for CAB+RPV LA in alternative outpatient facilities, this study used qualitative interviews informed by the Consolidated Framework for Implementation Research (CFIR), with 13 staff participating in the HOLA study (NCT06185452). Data analysis followed qualitative descriptive methods, assisted by Atlas.ti software version 22. The study adhered to the COREQ guidelines. Findings reveal five main factors to consider for implementation: operational and infrastructure adaptations, integrated management of human and organizational resources, need for coordination and follow-up, professional attitudes and work environment, and patient experience and patients’ needs perceived by professionals. This study emphasizes the comprehensive operational and infrastructure adaptations, adequate staff training, and supportive professional environment required for the successful implementation of CAB+RPV LA, while considering patients’ needs throughout the externalization process (trial registration number: NCT06643897).https://www.mdpi.com/1999-4915/17/7/993HIVantiretroviralscabotegravir + rilpivirine long actingout-of-hospital administrationimplementationbarriers and facilitators |
| spellingShingle | Diana Hernández-Sánchez Juan M. Leyva-Moral Julian Olalla Eugènia Negredo on behalf of the HOLA Study Group Barriers and Facilitators of Implementation of the Non-Hospital-Based Administration of Long-Acting Cabotegravir Plus Rilpivirine in People with HIV: Qualitative Data from the HOLA Study Viruses HIV antiretrovirals cabotegravir + rilpivirine long acting out-of-hospital administration implementation barriers and facilitators |
| title | Barriers and Facilitators of Implementation of the Non-Hospital-Based Administration of Long-Acting Cabotegravir Plus Rilpivirine in People with HIV: Qualitative Data from the HOLA Study |
| title_full | Barriers and Facilitators of Implementation of the Non-Hospital-Based Administration of Long-Acting Cabotegravir Plus Rilpivirine in People with HIV: Qualitative Data from the HOLA Study |
| title_fullStr | Barriers and Facilitators of Implementation of the Non-Hospital-Based Administration of Long-Acting Cabotegravir Plus Rilpivirine in People with HIV: Qualitative Data from the HOLA Study |
| title_full_unstemmed | Barriers and Facilitators of Implementation of the Non-Hospital-Based Administration of Long-Acting Cabotegravir Plus Rilpivirine in People with HIV: Qualitative Data from the HOLA Study |
| title_short | Barriers and Facilitators of Implementation of the Non-Hospital-Based Administration of Long-Acting Cabotegravir Plus Rilpivirine in People with HIV: Qualitative Data from the HOLA Study |
| title_sort | barriers and facilitators of implementation of the non hospital based administration of long acting cabotegravir plus rilpivirine in people with hiv qualitative data from the hola study |
| topic | HIV antiretrovirals cabotegravir + rilpivirine long acting out-of-hospital administration implementation barriers and facilitators |
| url | https://www.mdpi.com/1999-4915/17/7/993 |
| work_keys_str_mv | AT dianahernandezsanchez barriersandfacilitatorsofimplementationofthenonhospitalbasedadministrationoflongactingcabotegravirplusrilpivirineinpeoplewithhivqualitativedatafromtheholastudy AT juanmleyvamoral barriersandfacilitatorsofimplementationofthenonhospitalbasedadministrationoflongactingcabotegravirplusrilpivirineinpeoplewithhivqualitativedatafromtheholastudy AT julianolalla barriersandfacilitatorsofimplementationofthenonhospitalbasedadministrationoflongactingcabotegravirplusrilpivirineinpeoplewithhivqualitativedatafromtheholastudy AT eugenianegredo barriersandfacilitatorsofimplementationofthenonhospitalbasedadministrationoflongactingcabotegravirplusrilpivirineinpeoplewithhivqualitativedatafromtheholastudy AT onbehalfoftheholastudygroup barriersandfacilitatorsofimplementationofthenonhospitalbasedadministrationoflongactingcabotegravirplusrilpivirineinpeoplewithhivqualitativedatafromtheholastudy |